4.7 Article

Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 58, Issue 1, Pages 151-155

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.116.177931

Keywords

fibroblast activation protein; SPECT/CT imaging; collagen-induced arthritis; prednisolone phosphate encapsulating PEG liposomes; therapy monitoring

Funding

  1. NanoNextNL Drug Delivery Program [03D.06]

Ask authors/readers for more resources

Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation. Fibroblast activation protein (FAP) is overexpressed by fibroblastlike synoviocytes in arthritic joints. Radioimmunoimaging with an anti-FAP antibody might be used to monitor the response to therapy, thus enabling tailored therapy strategies and therapeutic outcomes. The aim of this study was to assess whether a radiolabeled anti-FAP antibody could be used to monitor the efficacy of treatment with long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a mouse model of arthritis. Methods: Collagen-induced arthritis (CIA) was induced in male DBA/1J mice. Mice were treated with a single injection (10 mg/kg) of PLP-LCL or empty LCL as a control. SPECT and CT images were acquired 24 h after injection of Tc-99m-labeled succinimidyl-hydrazinonicotinamide (Tc-99m-S-HYNIC) conjugated anti-FAP antibody 28H1 at 2, 5, and 9 d after treatment. The uptake of Tc-99m-S-HYNIC-28H1 in all joints was quantified and correlated with macroscopic arthritis scores. Results: Treatment of CIA with PLP-LCL significantly suppressed joint swelling. At just 1 d after treatment, the macroscopic arthritis scores had decreased by 50%. Scores decreased further, to only 10% of the initial scores, at 5 and 9 d after treatment. In contrast, macroscopic arthritis scores had increased up to 600% in untreated mice at 9 d after the injection of empty LCL. Tc-99m-S-HYNIC-28H1 uptake ranged from 1.5 percentage injected dose per gram in noninflamed joints to 22.6 percentage injected dose per gram in severely inflamed joints. The uptake of radiolabeled 28H1 in inflamed joints (percentage injected dose) correlated with the arthritis score (Spearman p, 0.77; P < 0.0001). Moreover, the uptake of (99)mTc-S-HYNIC-28H1 was slightly increased at 9 d after therapy but was not seen macroscopically, indicating that SPECT/CT imaging might be more sensitive than the macroscopic arthritis scoring method. Conclusion: SPECT/CT imaging with Tc-99m-S-HYNIC28H1 specifically monitored the response to therapy, and tracer accumulation correlated with the severity of inflammation. In addition, SPECT/CT imaging was potentially more sensitive than the macroscopic arthritis scoring method. This study showed that SPECT/CT with (TcS)-Tc-99m-HYNIC-28H1 could be used to noninvasively monitor the course of CIA in mice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation

Enrique J. Arenas, Alex Martinez-Sabadell, Irene Rius Ruiz, Macarena Roman Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquin Arribas

Summary: Immunotherapy has shown promise in cancer treatment, with T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) being potential tools for this approach. This study reveals that disruption of interferon-gamma signaling, including downregulation of JAK2, in cancer cells confers resistance to T cell-mediated cytotoxicity directed against HER2, highlighting a potential mechanism for resistance to T cell-engaging therapies.

NATURE COMMUNICATIONS (2021)

Correction Oncology

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity (vol 10, 575737, 2020)

Johannes Sam, Sara Colombetti, Tanja Fauti, Andreas Roller, Marlene Biehl, Linda Fahrni, Valeria Nicolini, Mario Perro, Tapan Nayak, Esther Bommer, Anne Schoenle, Maria Karagianni, Marine Le Clech, Nathalie Steinhoff, Christian Klein, Pablo Umana, Marina Bacac

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation

Pablo Moreno-Ruiz, Sara Corvigno, Nienke C. te Grootenhuis, Linnea La Fleur, Max Backman, Carina Strell, Artur Mezheyeuski, Gabriele Hoelzlwimmer, Christian Klein, Johan Botling, Patrick Micke, Arne Ostman

Summary: This study identifies high stromal FAP expression as a poor prognostic marker for survival in NSCLC patients, particularly in adenocarcinoma patients. Additionally, it reveals associations between α-SMA and FAP expression with specific clinical characteristics like p53 mutations and CD8 infiltration levels.

LUNG CANCER (2021)

Article Hematology

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Christian Augsberger, Gerulf Hanel, Wei Xu, Vesna Pulko, Lydia Jasmin Hanisch, Angelique Augustin, John Challier, Katharina Hunt, Binje Vick, Pier Eduardo Rovatti, Christina Krupka, Maurine Rothe, Anne Schonle, Johannes Sam, Emmanuelle Lezan, Axel Ducret, Daniela Ortiz-Franyuti, Antje-Christine Walz, Jorg Benz, Alexander Bujotzek, Felix S. Lichtenegger, Christian Gassner, Alejandro Carpy, Victor Lyamichev, Jigar Patel, Nikola Konstandin, Antje Tunger, Marc Schmitz, Michael Von Bergwelt-Baildon, Karsten Spiekermann, Luca Vago, Irmela Jeremias, Estelle Marrer-Berger, Pablo Umana, Christian Klein, Marion Subklewe

Summary: The novel T-cell bispecific (TCB) antibody targets intracellular antigens, recognizing multiple leukemia-associated targets. WT1-TCB demonstrates potent killing of AML cells through various methods, with enhanced cytotoxicity when combined with immunomodulatory drugs.

BLOOD (2021)

Article Immunology

Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells

Vittoria Massafra, Sofia Tundo, Aline Dietzig, Axel Ducret, Christian Jost, Christian Klein, Roland E. Kontermann, Hendrik Knoetgen, Martin Steegmaier, Andrea Romagnani, Yvonne A. Nagel

Summary: This study explores the potential of targeted protein degradation in tumor cells to enhance T cell effector function, and for the first time investigates the impact of combining a degrader and a TCB in cancer immunotherapy.

JOURNAL OF IMMUNOLOGY (2021)

Article Biology

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

S. Jordan Kerns, Chaitra Belgur, Debora Petropolis, Marianne Kanellias, Riccardo Barrile, Johannes Sam, Tina Weinzierl, Tanja Fauti, Anne Freimoser-Grundschober, Jan Eckmann, Carina Hage, Martina Geiger, Patrick Ray Ng, William Tien-Street, Dimitris Manatakis, Virginie Micallef, Regine Gerard, Michael Bscheider, Ekaterina Breous-Nystrom, Anneliese Schneider, Anna Maria Giusti, Cristina Bertinetti-Lapatki, Heather Shannon Grant, Adrian B. Roth, Geraldine A. Hamilton, Thomas Singer, Katia Karalis, Annie Moisan, Peter Bruenker, Christian Klein, Marina Bacac, Nikolce Gjorevski, Lauriane Cabon

Summary: This study demonstrated the unprecedented capability of two human Organs-on-Chips in evaluating the safety profile of T-cell bispecific antibodies targeting tumor antigens, predicting TCB safety liabilities based on target expression and antibody affinity. These novel tools broaden research options for understanding engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.

ELIFE (2021)

Article Biochemistry & Molecular Biology

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies

Steffen Dickopf, Can Buldun, Vedran Vasic, Guy Georges, Carina Hage, Klaus Mayer, Matthias Forster, Uwe Wessels, Kay-Gunnar Stubenrauch, Jorg Benz, Andreas Ehler, Matthias E. Lauer, Philippe Ringler, Sebastian Kobold, Stefan Endres, Christian Klein, Ulrich Brinkmann

Summary: The field of multi-specific antibody derivatives is rapidly growing, with domain exchange reactions being able to generate hybrid antibodies under physiological conditions for potential therapeutic applications.

BIOLOGICAL CHEMISTRY (2022)

Article Medicine, Research & Experimental

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Alvaro Teijeira, Itziar Migueliz, Saray Garasa, Vaios Karanikas, Carlos Luri, Asunta Cirella, Irene Olivera, Marta Canamero, Maite Alvarez, Maria C. Ochoa, Ana Rouzaut, Maria E. Rodriguez-Ruiz, Miguel F. Sanmamed, Christian Klein, Pablo Umana, Mariano Ponz, Marina Bacac, Ignacio Melero

Summary: In this study, the performance of the CEA-CD3 T cell bispecific antibody cibisatamab in three-dimensional tumor organoids cocultured with T cells was investigated using time-lapse confocal microscopy. The results showed that the killing of tumor cells was dependent on the levels of surface CEA expression, and the higher affinity CEACAM5-CD3 bispecific antibody remained active on low CEA expressing organoids. Additionally, the coculture of tumor organoids, autologous fibroblasts, and T cells demonstrated a costimulatory effect of anti-FAP-4-1BBL antibody, leading to enhanced tumor cell killing.

THERANOSTICS (2022)

Article Oncology

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils

Gabrielle Leclercq, Llucia Alberti Servera, Sabrina Danilin, John Challier, Nathalie Steinhoff, Claudia Bossen, Alex Odermatt, Valeria Nicolini, Pablo Umana, Christian Klein, Marina Bacac, Anna-Maria Giusti, Anneliese Schneider, Helene Haegel

Summary: This study investigated the biological mechanisms of cytokine release after treatment with T cell bispecific antibodies (TCBs) and identified T cells as the triggers and monocytes and neutrophils as the amplifiers of the cytokine cascade. Moreover, it demonstrated the contribution of neutrophils to TCB-mediated cytokine release using single-cell RNA sequencing.

ONCOIMMUNOLOGY (2022)

Article Oncology

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

Gabrielle Leclercq, Helene Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Lariviere, Alex Odermatt, Martin Stern, Pablo Umana, Marina Bacac, Christian Klein

Summary: This study aimed to identify small molecules that can reduce cytokine release while maintaining T cell-mediated tumor killing. By screening a library of FDA-approved kinase inhibitors, mTOR, JAK, and Src kinase inhibitors were found to modulate cytokine release. Further in vitro and in vivo experiments confirmed these findings and supported the evaluation of these inhibitors as a treatment to prevent cytokine release syndrome (CRS).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Oncology

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors

Gabrielle Leclercq, Nathalie Steinhoff, Helene Haegel, Donata De Marco, Marina Bacac, Christian Klein

Summary: T cell engaging therapies redirect T cells towards tumor cells, leading to cytotoxicity. However, this can trigger a release of pro-inflammatory cytokines causing Cytokine Release Syndrome (CRS), which remains a major safety concern. Mitigation strategies are necessary to reduce cytokine release while maintaining efficacy. Tyrosine kinase inhibitors are emerging as a potential strategy for managing CRS symptoms.

ONCOIMMUNOLOGY (2022)

Review Oncology

Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review

Andrew Davies, Arnon P. Kater, Jeff P. Sharman, Stephan Stilgenbauer, Umberto Vitolo, Christian Klein, Joana Parreira, Gilles Salles

Summary: The type II anti-CD20 antibody obinutuzumab has shown improved efficacy compared to rituximab in the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). Ongoing research is focusing on biomarkers and developing chemotherapy-free regimens involving obinutuzumab.

FUTURE ONCOLOGY (2022)

Article Cell Biology

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge

Summary: This study showed that contact between tumor cells and stromal cells inhibits the effector functions of Obinutuzumab, highlighting the potential for improved therapies targeting the microenvironment to enhance patient outcomes in B-cell malignancies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Review Medicine, Research & Experimental

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

Marlena Surowka, Wolfgang Schaefer, Christian Klein

Summary: CrossMab technology, introduced in 2011, enables correct light-chain and heavy-chain association in bispecific antibodies and has become one of the most mature and widely applied technologies in the field. Multiple bispecific antibodies based on CrossMab technology have entered clinical trials, demonstrating potential therapeutic value in different disease settings.
Meeting Abstract Oncology

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.

Stephan Wullschleger, Melanie Tichet, Laura Codarri-Deak, Pablo Umana, Christian Klein, Douglas Hanahan

CANCER RESEARCH (2021)

No Data Available